- Home
- STTK vs HOWL Comparison
STTK vs HOWL Comparison
Compare STTK & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HOWL
- Stock Information
- Founded
- STTK 2016
- HOWL 2017
- Country
- STTK United States
- HOWL United States
- Employees
- STTK N/A
- HOWL N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- HOWL Health Care
- Exchange
- STTK Nasdaq
- HOWL Nasdaq
- Market Cap
- STTK 37.6M
- HOWL 37.9M
- IPO Year
- STTK 2020
- HOWL 2021
- Fundamental
- Price
- STTK $0.91
- HOWL $0.99
- Analyst Decision
- STTK Hold
- HOWL Strong Buy
- Analyst Count
- STTK 4
- HOWL 3
- Target Price
- STTK $3.00
- HOWL $8.33
- AVG Volume (30 Days)
- STTK 108.4K
- HOWL 270.1K
- Earning Date
- STTK 05-01-2025
- HOWL 05-08-2025
- Dividend Yield
- STTK N/A
- HOWL N/A
- EPS Growth
- STTK N/A
- HOWL N/A
- EPS
- STTK N/A
- HOWL N/A
- Revenue
- STTK $4,606,000.00
- HOWL $1,143,000.00
- Revenue This Year
- STTK N/A
- HOWL N/A
- Revenue Next Year
- STTK N/A
- HOWL $733.33
- P/E Ratio
- STTK N/A
- HOWL N/A
- Revenue Growth
- STTK 69.65
- HOWL N/A
- 52 Week Low
- STTK $0.69
- HOWL $0.60
- 52 Week High
- STTK $11.76
- HOWL $5.73
- Technical
- Relative Strength Index (RSI)
- STTK 47.64
- HOWL 55.55
- Support Level
- STTK $0.84
- HOWL $0.80
- Resistance Level
- STTK $1.00
- HOWL $1.07
- Average True Range (ATR)
- STTK 0.09
- HOWL 0.09
- MACD
- STTK 0.01
- HOWL 0.02
- Stochastic Oscillator
- STTK 42.02
- HOWL 70.37
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.